The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
The clearance of the Binx io CT/NG test marks a milestone for the Johns Hopkins University group that funds early-stage development of rapid STI testing.
Illumina plans to upgrade all its NIPT customers to version 2 of its VeriSeq solution over the next year.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
The Cyprus-based company has been offering a cell-free DNA-based noninvasive prenatal test for fetal aneuploidies, called Veracity, since 2015.
During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.
The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.
Last month, the Cyprus-based genetic diagnostics company launched a number of hereditary cancer and somatic tumor sequencing panels, its first tests for oncology.
The funding will be used to support clinical validation and expand market access for the firm's endometriosis diagnostic test.
Under the partnership, Heidelberg-based Eluthia will become the primary distributor of BGI's NIFTY noninvasive prenatal test in Germany.
Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.
NYU Winthrop has granted Progenity an exclusive license to patents that it holds covering a biomarker for predicting preterm births.
A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.
Some at-home infectious disease tests and sample collection kits exist in a murky regulatory realm, and their sale to patients is troubling laboratorians and clinicians.
The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.
Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.